Special Issue

Brain Imaging and Cognitive Deficits in Psychiatric Disorders

Message from the Guest Editor

Cognitive deficits exist in psychiatric disorders, such as schizophrenia, major depressive disorder, and bipolar disorder; however, the brain structural and functional dysconnectivity underlying cognitive deficits remain unclear. The goal of this Special Issue is to focus on the roles of brain connectivity and the neuropathological mechanisms underlying cognitive deficits as well as clinical symptoms in psychiatric disorders. We aim to collect articles that report on high-quality research, from basic benchwork to neuroimaging and clinical trials. We will also address important conceptual and methodological questions. We welcome original research and reviews related to this topic. The articles are encouraged to cover the following research areas:

- Structure and function of brain connectivity in psychiatric disorders.
- Cognitive deficits and clinical symptoms associated with brain connectivity in psychiatric disorders.
- Genetic and molecular bases of brain connectivity in schizophrenia, especially those relevant to cognitive functioning in psychiatric disorders.
- Effects of pharmacological treatment on cognition and brain connectivity in psychiatric disorders.

Guest Editor

Prof. Dr. Wenbin Guo

Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Deadline for manuscript submissions

closed (30 April 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/175266

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).